Cytoagents logo final cmyk
Cytoagents logo final cmyk

CytoAgents

CytoAgents is a clincal-stage biotech company creating a platform to treat viral epidemics and global pandemics like COVID-19.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Pittsburgh, PA, USA
  • Currency USD
  • Founded December 2018
  • Employees 4
  • Incorporation Type C-corp
  • Website cytoagents.com

Company Summary

CytoAgents is a clinical-stage biotech company focused on the development of innovative pharmaceutical products for the treatment of COVID-19, influenza, viral infectious diseases and conditions that cause acute respiratory distress. Our lead compound, GP1681, targets the underlying cause of life-threatening respiratory distress, cytokine release syndrome, by modulating the body’s natural immune response to sickness or disease.

Team

  • Teresa Whalen, CEO is a pharmacist by trade and has 25+ years of experience in the healthcare industry. She is a proven leader in the areas of sales leadership, developing go to market strategies and managing strategic partnerships. She is a seasoned executive with experience spanning large companies, Siemens Medical, to startups with successful exits. She is focused on strategy, business funding and developing strategic partnerships.

  • LinkedIn profile:
    https://www.linkedin.com/in/williamfrederick/

  • Default avatar
    Todd Lorenz, MD
    Chief Medical Officer

    LinkedIn profile:
    https://www.linkedin.com/in/todd-lorenz-4357026/

  • Default avatar
    Jodi Craigo, PhD
    Chief Science Officer

    Linkedin profile:
    https://www.linkedin.com/in/jodicraigo/

Advisors

  • Default avatar
    Dr. Michael Ison, MD, MS Board Certified Infectious Disease Northwestern
    Unconfirmed
    Default avatar
    Dr. Paul Thomas, PhD Full Member, Dept. of Immunology St. Jude Children's Research Hospital
    Unconfirmed
    Default avatar
    Dr. Albert Osterhaus, PhD Chair EU Group on Influenza > 1,200 publications
    Unconfirmed
  • Default avatar
    Dr. Hank Safferstein, PhD, JD, MBA EIR UPMC Enterprises CEO Generian
    Unconfirmed

Previous Investors

  • Default avatar
    Blue Tree Allied Angels
    Unconfirmed
    Default avatar
    Innovation Works
    Unconfirmed
    Default avatar
    Next Act Fund
    Unconfirmed
  • Default avatar
    Delaware Crossing
    Unconfirmed
    Default avatar
    Pittsburgh Life Sciences Greenhouse
    Unconfirmed